News
Asarina Pharma Phase IIB Study receives surge in applicants volunteering for new PMDD treatment—on its first day live
2018-04-16 15:00
The phase IIB study aims to recruit 225-250 patients in total from Sweden, UK, Germany and Poland. Successfully approving 29 patients to begin the trial...
Asarina Pharma recruits patients for Phase IIB trial of Sepranolone, world’s first treatment targeting PMDD, premenstrual dysphoric disorder
2018-04-04 14:00
Worldwide, 4-5% of all women of a fertile age currently suffer from PMDD. Symptoms can be devastating and disabling, disrupting relationships, family and...